Rastogi_2017

Supportive Therapie · Version 2.1

Referenz

(Autor, Jahr, Journal)

Studientyp

Mono- vs. Multizentrisch, Verblindung, Randomisierung, Arme, Fallzahl n, Land, Zeitraum

 

Patienten-merkmale

Indikation, Alter, Geschlecht (m/w)

Intervention

Fallzahl n, Beschreibung der präventiven bzw. therapeutischen Maßnahme

Kontrolle

Fallzahl n, Beschreibung der präventiven Maßnahme bzw. therapeutischen Maßnahme

Zielgrößen

Primärer Endpunkt

Sekundäre(r) Endpunkt(e)

Primärer Endpunkt

Angaben für Intervention vs. Kontrolle

Sekundäre(r) Endpunkt(e)

Angaben für Intervention vs. Kontrolle

Finanzierung

Evidenzstufe

Bei Abwertung: Angabe von Gründen

Bewertung des Autors

Rastogi

 

2017

 

Journal of the Egyptian National Cancer Institute

single institutional, retrospective study

 

2 arms

 

n = 35

 

India

 

09/2012 – 08/ 2016

N = 35

 

adenocarcinoma of prostate

 

IG-IMRT-M

Median Age (range): 68y (56–79)

 

IG-IMRT-B

Median Age (range): 74y (55–90)

 

median dose of RT: 76 Gray (range 74–78 Gray)

 

mean duration of radiotherapy: IG-IMRT-B: 57 ± 2 days

IG-IMRT-M: 56 ± 2 days

 

 

N = 17

 

gold marker registration based IG-IMRT (IG-IMRT-M)

N = 18

 

bony landmark registration based IG-IMRT (IG-IMRT-B)

prostate motion variability

 

acute and late GI and GU toxicities

prostate variability observed with and without markers in millimetre:

4.1 ± 2.3 vs 3.7 ± 2.1 [Antero-Posterior (A-P); p = 0.001], 2.3 ± 1.5 vs 2.1 ± 1.2 [Superior-Inferior (S-I);

p = 0.095] and 1.1 ± 1.7 vs 0.4 ± 1.4 [Left-Right (L-R); p = 0.003].

 

IG-IMRT-B vs. IG-IMRT-M

 

grade ≥ 2 diarrhea: 50% vs. 11%,

 OR = 7.5 (1.3–42.7); p = 0.02

garde ≥ 2 proctitis: 38% vs 5.8%, OR = 10.1 (1.09–94.1); p = 0.04

 

median follow up of 36 months

late genitourinary toxicities grade ≥ 2: 27% vs 0%; p = 0.04

 

none

3

small sample size
no blinding
no randomisation

"IG-IMRT-M detects higher prostate motion variability as compared to IG-IMRT-B, inferring a significant prostate motion inside fixed pelvic bony cavity. The addition of marker based image guidance results in higher precision of prostate localization and lesser acute and late toxicities."